Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia

Haematologica

Volumn 86, Issue 10, 2001, Pages 1046-1050

  Lauria, F ^a   Lenoci, M ^a   Annino, L ^a   Raspadori, D ^a   Marotta, G ^a   Bocchia, M ^a   Forconi, F ^a   Gentili, S ^a   La Manda, M ^a   Marconcini, S ^a   Tozzi, M ^a   Baldini, L ^a   Zinzani, P L ^a   Foa R ^a  

^a Department of Hematology   (Italy)

Author keywords

2 CdA; Anti CD20; DCF; HCL; Rituximab

Indexed keywords

ALPHA INTERFERON; CD20 ANTIGEN; CLADRIBINE; PENTOSTATIN; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; BONE PAIN; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HAIRY CELL LEUKEMIA; HUMAN; HYPOTENSION; LEUKEMIA REMISSION; MALE; NEUTROPENIA; RECURRENT DISEASE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; REMISSION INDUCTION; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0034766754     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. α-interferon for induction of remission in hairy-cell leukemia
2. α-2-interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients
3. Remission in hairy-cell leukemia with pentostatin (2′-deoxycoformycin)
4. Long term results with 2′deoxycoformycin in hairy cell leukemia
5. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin
6. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
7. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications
8. IDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
9. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
10. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
11. Levels of expression of CD19 and CD20 in chronic B cell leukaemias
12. Consensus resolution: Proposed criteria for evaluation of response to treatment in hairy cell leukemia
13. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience
14. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: A 5-year survey
15. Longterm follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine
16. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: A report of 979 patients
17. Responses in refractory hairy cell leukemia to a recombinant immunotoxin
18. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
19. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
20. Rituximab sequentiallly administered to a first line treatment with CHOP chemotherapy in follicular non-Hodgkin's lymphoma patients
21. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine
22. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients